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(TKR) [5], with substantial implications in 
terms of healthcare costs and patients’ pro-
ductivity for recurrent and prolonged inpa-
tient stay [6-8].
In the last few years several studies have eva-
luated the economic impact of VTE. Recent 
estimates confirm that thromboembolism-
attributable costs are more than $1.5 billion/
year in the US [9]. In the same review, the 
authors highlighted that costs of acute venous 
episodes exceed $20,000 in certain patients’ 
categories. In a recent US study on Medicare 
beneficiaries [3], THR or THK patients deve-
loping VTE were found to have statistically 
INTRODUCTION
Venous thromboembolism (VTE) is the third 
most common cardiovascular illness after 
acute coronary syndrome and stroke [1], 
affecting more than 1 million patients each 
year [2]. It includes two different conditions, 
pulmonary embolism (PE) and deep vein 
thrombosis (DVT), which are relevant rea-
sons of mortality and morbidity worldwide 
[3,4]. Without an efficacious prophylaxis, 
risk of developing VTE is estimated around 
42-57% in patients undergoing total hip re-
placement (THP), and around 41-85% in 
patients undergoing total knee replacement 
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ABSTRACT
BACKGROUND: Venous thromboembolism (VTE) is a common and burdensome cardiovascular condition, frequently 
leading to severe complications and requiring high-cost healthcare interventions. New oral anticoagulants (nOACs) have 
demonstrated to be efficacious and safe in VTE prevention of patients undergoing total hip replacement (THR) and total 
knee replacement (TKR), a condition that is typically associated to cardiovascular disease. The Italian Healthcare Service 
(SSN) has recently approved the latest nOAC, apixaban. The present article aims to evaluate its economic impact in the 
perspective of the Italian SSN.
METHODS: We conducted a budget impact analysis to estimate clinical outcomes and economic consequences associated 
to the reimbursement of apixaban, in the prevention of VTE as a consequence of major orthopedic surgery, over a three-year 
time horizon. In our analysis we compared two alternative scenarios, with apixaban either reimbursed (Scenario B) or not 
reimbursed (Scenario A) by the Italian SSN, and estimated the difference of healthcare costs between the two scenarios. 
Only direct healthcare costs have been considered.
RESULTS: According to market assumptions, it is estimated that 1.2%, 3.7%, and 6.5% of THR patients, and 1.2%, 3.8% 
and 6.7% of TKR patients, would be treated with apixaban over the first three years since launch. At the estimated daily cost 
of apixaban (€2.48/die), this would translate into a budget impact of €14.3 mln, €45.5 mln, and €81.4 mln at years 1, 2 and 
3 since launch, respectively. This expenditure would be more than offset by savings, due to: i) reduction of prescriptions of 
alternative treatment options (other nOACs, low-molecular weight heparins, fondaparinux); ii) reduction of the economic 
burden attributable of CV complications of VTE. Finally, Scenario B resulted slightly favourable compared to Scenario 
A, leading to economic savings for about €50 thousands over three years. Sensitivity analyses confirmed findings of the 
base-case analysis.
CONCLUSIONS: Reimbursement of apixaban does not determine a budget impact increase for Italian SSN. Its usage may 
be considered fully sustainable from a pharmaco-economic viewpoint. 
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significant higher costs, mortality and risk 
of rehospitalisation at one year after hospital 
discharge, compared to matched non-VTE 
patients. In a recent paper, Rupert et al. [10] 
reviewed ten economic studies carried out in 
the US and Europe, analyzing costs of THR 
and TKR patients developing VTE in the US 
and Europe. Evidence in this review pointed 
out that orthopaedic patients having PE and 
DVT costs up to more than twice than simi-
lar patients (controls) without any cardiova-
scular complications. Moreover, results from 
US administrative databases showed cost 
variability, with economic burden between 
US$3,000-9,500 for an initial episode. These 
costs seem higher than costs in the Europe-
an Union, where VTE hospital management 
costs were €1,800 and €3,200 after 3 months 
and 1 year since diagnosis, respectively. Lon-
ger permanence in intensive coronary units, 
longer length stay, increasing usage of drug 
and outpatient services significantly increase 
direct healthcare costs of these patients [11]. 
Moreover, adopting a longer time horizon 
should take into account long-term clinical 
consequences of DVT such as recurrent DVT 
[12], post-thrombotic syndrome (PTS) [13] 
and thromboembolic pulmonary hyperten-
sion (PH) [14].
New oral anticoagulants (nOACs), apixaban, 
rivaroxaban and dabigatran, have demonstra-
ted to reduce the risk of VTE after TKR and 
THR surgery, and to be as safe as low-mole-
cular weight heparins (LMWH), enoxaparin 
in particular [15-22]. Although these new tre-
atments have significantly improved patients’ 
outcomes in the last years, some concerns 
have been raised on their cost-effectiveness 
profile, due to the high daily costs. In parti-
cular, healthcare payers have expressed the 
need of evaluating the inclusion of nOACs in 
formularies in the light of the budget implica-
tions of their possible increasing usage. The 
present study aims to analyze the economic 
impact of reimbursing and funding apixaban 
for prevention of VTE after THR or TKR, 
from the perspective of the Italian healthcare 
system.
MATERIAL AND METHODS
The present analysis evaluates the econo-
mic and clinical implications of reimbursing 
apixaban in Italy for VTE prevention in pa-
tients undergoing THR and TKR interven-
tions, over the first three years after market 
authorization and reimbursement.
Model design and key 
analysis parameters
To perform this analysis, a decision-analyti-
cal budget impact model (BIM) running in 
Microsoft Excel® was developed. The model 
estimates financial impact (healthcare costs 
and investments) and clinical benefits (num-
ber of avoided VTE episodes) of alternative 
treatment scenarios which would likely re-
flect future trends of VTE prevention in Italy. 
Costs and outcomes for each hypothetical 
scenario have been evaluated on a short-time 
horizon (90 days). Figure 1 illustrates the de-
cision tree built to run the analysis.
Figure 1. Graphical representation of the decision tree adopted in the budget impact analysis
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A patient undergoing THR or TKR is treated 
to prevent VTE events. During the follow-
up period the patient could have a certain li-
kelihood to develop different forms of fatal 
or non-fatal VTE (PE or DVT), as well as 
bleeding events with different severity. Di-
stribution of patients within the flow, as well 
as overall management costs, depends on the 
drug received. In the budget impact analysis, 
two different scenarios were defined and 
compared to each other:
 - “Apixaban not reimbursed” scenario (de-
fined “Scenario A”), assuming that apixa-
ban would not be reimbursed and funded 
by Italian National Healthcare Service 
(SSN);
 - “Apixaban reimbursed” scenario (defined 
“Scenario B”), assuming that apixaban 
would be reimbursed and funded by Ita-
lian SSN.
Assumptions on patients distribution for both 
scenarios, in terms of drug prescription, were 
built using current data of patients’ treatment 
as reference, from updated market data [23]. 
According to current data, low molecular 
weight heparins represent the standard tre-
atment for VTE prevention (administered to 
almost 90% of THR and TKR receiving VTE 
prevention, with enoxaparin being the most 
prescribed therapy). Fondaparinux and nO-
ACs (rivaroxaban and dabigatran) are used in 
selected cases only. Table I shows the ex-
pected patients’ treatment distribution in the 
next three years after apixaban market autho-
rization, according to scenario (apixaban 
reimbursed vs. apixaban not reimbursed) and 
indication (VTE prevention in THR and 
TKR).
Treatment
Relative frequency, THR (%) Relative frequency, TKR (%)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Scenario A: apixaban not reimbursed by Italian SSN
Apixaban 0.0 0.0 0.0 0.0 0.0 0.0
Low molecular weight heparins 89.1 84.1 81.3 89.1 84.2 81.5
Rivaroxaban 3.9 6.8 8.5 3.8 6.7 8.4
Dabigatran 3.0 5.0 5.9 3.0 4.9 5.8
Fondaparinux 4.0 4.2 4.3 4.0 4.2 4.3
Total 100.0 100.0 100.0 100.0 100.0 100.0
Scenario B: apixaban reimbursed by Italian SSN
Apixaban 1.2 3.7 6.5 1.2 3.8 6.7
Low molecular weight heparins 88.0 81.0 76.0 88.0 81.0 76.0
Rivaroxaban 3.8 6.4 8.0 3.8 6.4 7.8
Dabigatran 3.0 4.8 5.5 3.0 4.8 5.4
Fondaparinux 4.0 4.0 4.0 4.0 4.0 4.0
Total 100.0 100.0 100.0 100.0 100.0 100.0
Table I. Distribution of patients, by indication and treatment: expected trends after apixaban market authorization
For the present analysis, the perspective of 
the Italian SSN was adopted. The healthca-
re direct costs were measured over a 3-years 
period (with results split by year). Costs after 
the first year since apixaban market authori-
zation in Italy were discounted at an annual 
rate of 3.5%, while clinical outcomes were 
not discounted. Costs were measured in Euro 
(€) 2012.
Patient population
In order to calculate the overall budget im-
pact of VTE prevention in Italy, we estimated 
the annual number of patients receiving VTE 
pharmacological prevention due to THR and 
TKR interventions. Italian population at De-
cember 31st, 2010 (60.62 million inhabitants) 
and expected annual percentage increase in 
population (0.47%) were retrieved from the 
National Statistics Institute (ISTAT) [24]. A 
recent report, published in 2009 by the Supe-
rior Health Institute (ISS) [25], estimated that 
annual incidence of TKR and THR is 0.12% 
and 0.10% respectively. According to 2010 
internal market research data [26], 96% of 
THR patients and 93% TKR patients would 
receive VTE pharmacological prevention. 
Assuming that percentage of treated patients 
would not change over time, the estimated an-
nual number of treated patients at years 1, 2 
and 3 (after apixaban market authorization) is 
71.16, 75.08, 79.21 thousands for THR, and 
63.37, 66.60 and 69.99 thousands for TKR.
Therapy duration and hospital 
length of stay data
Duration of therapy for apixaban and the 
other drugs indicated in VTE prevention has 
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Clinical data
Efficacy data for this analysis were derived 
from a mixed-treatment comparison evalua-
ting evidence from clinical trials on VTE pre-
vention in people undergoing elective THR 
and TKR surgery [28]. In absence of head-to-
head clinical trials this metanalysis allowed to 
establish an indirect comparison of main clini-
cal outcomes among VTE prevention tre-
atments. This metanalysis was carried out ac-
cording to NICE (National Institute of Clinical 
Excellence) requirements, and used as basis to 
build the economic evaluation of NICE single 
technology appraisal (STA) [29] Data for this 
metanalysis were selected through a systema-
tic review, including the following clinical stu-
dies: double-blind randomised controlled trials 
(RCTs) of pharmacological prophylaxis of 
VTE in patients undergoing elective THR and 
TKR; trials enrolling mixed hip and knee po-
pulations, provided that patients undergoing 
hip surgery were randomised separately from 
patients undergoing knee surgery and patient 
numbers and results were stratified by surgery 
population; phase II trials, provided these were 
double-blind randomised controlled trials. Cli-
nical evidence regarded LMWH, fondapari-
nux, rivaroxaban, dabigatran and apixaban, 
which could have been compared with either 
placebo or any of the treatments indicated in 
VTE prevention. Metanalysis measured two 
main clinical indicators: occurrence of VTE 
events (including pulmonary embolism, PE: 
symptomatic and asymptomatic deep vein 
thrombosis, DVT); occurrence of a bleeding 
events (major, non-major, minor events). In 
case of absence of calculated data for a certain 
drug, the rate of adverse events was assumed 
to be the lowest among compared treatments. 
Finally, rate of adverse events was stratified by 
distal vs. proximal DVT and fatal vs. non-fatal 
PE, using a conditional post-event distribution 
[28]. According to our assumptions, fatal 
events occurred in 12.5% and 25.0% of PE ca-
ses, for THR and TKR, respectively. Major 
bleedings represented 7.5% of all total blee-
ding events, for both THR and TKR patients. 
Table IIIa and Table IIIb illustrate, respecti-
vely, adverse events and death incidence rates 
(by drug and indication) and conditional distri-
bution of post-event rates.
Economic data and assumptions 
on resource consumption
As the Italian SSN perspective was adopted in 
the analysis, only direct healthcare costs were 
measured. Overall VTE prevention therapy 
costs, inpatient costs for THR and TKR surge-
ry, costs of VTE complications and bleedings 
were identified in our research. Figure 2 shows 
daily costs for pharmacological treatment.
Treatment
THR TKR
Total VTE 
+ all cause 
death rate (%)
Bleeding 
events rate 
(%)
Total VTE 
+ all cause 
death rate (%)
Bleeding 
events rate 
(%)
a) Incidence of VTE and bleeding events
Apixaban 1.9 8.7 17.4 5.6
Low molecular weight heparins 5.4 9.4 27.4 7.2
Rivaroxaban 1.6 9.4 14.2 7.6
Dabigatran 4.8 10.0 26.3 7.0
Fondaparinux 1.7 8.7 11.3 6.2
THR TKR
b) Distributions of VTE events and bleeding by severity/type
PE events (% of total events) 3.6 3.6
Fatal (% of PE events) 12.5 25.0
Non-fatal (% of PE events) 87.5 75.0
Symptomatic DVT events (% of total events) 2.6 4.5
Distal (% of symptomatic DVT events) 16.7 80.0
Proximal (% of symptomatic DVT events) 83.3 20.0
Asymptomatic DVT events (% of total events) 93.8 91.4
Distal (% of asymptomatic DVT events) 73.8 91.2
Proximal (% of asymptomatic DVT events) 26.2 8.8
Non-VTE death events (% of total events) 3.5 3.5
All VTE events + non-VTE deaths (% of total events) 100.0 100.0
Major bleedings (% of total bleeding events) 7.5 7.5
Non major bleedings (% of total bleeding events) 34.1 34.1
Minor bleedings(% of total bleeding events) 58.3 58.3
All bleeding events (% of total events) 100.0 100.0
Table III. Efficacy data used in the model: a) adverse events and death incidence rates; b) conditional distribution of post-event rates
Figure 2. Daily treatment costs of therapies indicated in VTE prevention 
(enoxaparin 40 mg: 4,000 International Units – IU)
OD = once daily; TD = twice daily
ted during inpatient stay (for the orthopaedic 
replacement intervention) and then continued 
at home after discharge. Distinction between 
hospital and domiciliary treatment was neces-
sary, as cost of pharmacological treatments in 
Italy could be different in the two settings (cfr 
“Economic Data”). Assumptions on length of 
stay (by type of replacement surgery) were 
obtained from a study measuring resource 
consumption and economic burden of hip and 
knee replacement interventions in Italy [27].
been estimated in order to calculate treatment 
costs. Table II shows treatment duration as-
sumptions, by therapy, treatment setting, and 
type of replacement surgery.
In this budget impact model it was assumed 
that overall treatment duration for each drug 
was the same as in clinical trials submitted for 
EMA approval. According to clinical trials 
data, overall duration of treatment is simi-
lar for all drugs except dabigatran, which is 
shorter. It is assumed that treatment is initia-
Treatment
Duration of treatment, THR (days) Duration of treatment, TKR (days)
Hospital 
inpatient
After 
discharge
Total
Hospital 
inpatient
After 
discharge
Total
Apixaban 10.0 25.0 35.0 9.0 5.0 14.0
Low molecular weight heparins 10.0 25.0 35.0 9.0 5.0 14.0
Rivaroxaban 10.0 25.0 35.0 9.0 5.0 14.0
Dabigatran 10.0 21.5 31.5 8.0 0.0 8.0
Fondaparinux 10.0 25.0 35.0 9.0 5.0 14.0
Table II. Duration of treatment, by indication and therapy setting
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With regard to apixaban, daily cost was cal-
culated applying SSN rebates to the official 
ex-manufacturer price, published in the Of-
ficial Gazette [30]. For the other therapies, a 
weighted average of inpatient and outpatient 
costs was used. Distinction between inpatient 
and outpatient costs was necessary as patients 
receiving initial treatment during hospitaliza-
tion could continue therapy after discharge, if 
duration of treatment was longer than length 
of hospital stay (Table II). In our research, it 
was found that price of each marketed drug 
substantially varied among regions. Two 
main reasons determined this variability. 
First, Italian hospitals (or groups of hospi-
tals) can negotiate prices with manufacturers 
through tenders, thus resulting in potentially 
different tender prices. Second, regions and 
local health units can discretionarily decide 
customized strategies to distribute heparins 
for outpatient use (i.e. direct distribution via 
hospitals, direct distribution via public phar-
macies, standard retail distribution via public 
pharmacies), resulting again in different final 
prices for the SSN.
In order to obtain daily treatment costs being 
representative of the whole regional variabi-
lity, we calculated average prices weighting 
regional prices by frequency of usage of a 
distribution channel and regional population. 
Regional prices and frequency of adoption 
of a certain distribution model were retrie-
ved using multiple sources (internal market 
research data, official documentation on ho-
spital tenders, etc.) Regional population data 
were finally extracted from Italian National 
Statistics sources (ISTAT data, December 31st 
2010 [31]).
Clinical data
Efficacy data for this analysis were derived 
from a mixed-treatment comparison evalua-
ting evidence from clinical trials on VTE pre-
vention in people undergoing elective THR 
and TKR surgery [28]. In absence of head-to-
head clinical trials this metanalysis allowed to 
establish an indirect comparison of main clini-
cal outcomes among VTE prevention tre-
atments. This metanalysis was carried out ac-
cording to NICE (National Institute of Clinical 
Excellence) requirements, and used as basis to 
build the economic evaluation of NICE single 
technology appraisal (STA) [29] Data for this 
metanalysis were selected through a systema-
tic review, including the following clinical stu-
dies: double-blind randomised controlled trials 
(RCTs) of pharmacological prophylaxis of 
VTE in patients undergoing elective THR and 
TKR; trials enrolling mixed hip and knee po-
pulations, provided that patients undergoing 
hip surgery were randomised separately from 
patients undergoing knee surgery and patient 
numbers and results were stratified by surgery 
population; phase II trials, provided these were 
double-blind randomised controlled trials. Cli-
nical evidence regarded LMWH, fondapari-
nux, rivaroxaban, dabigatran and apixaban, 
which could have been compared with either 
placebo or any of the treatments indicated in 
VTE prevention. Metanalysis measured two 
main clinical indicators: occurrence of VTE 
events (including pulmonary embolism, PE: 
symptomatic and asymptomatic deep vein 
thrombosis, DVT); occurrence of a bleeding 
events (major, non-major, minor events). In 
case of absence of calculated data for a certain 
drug, the rate of adverse events was assumed 
to be the lowest among compared treatments. 
Finally, rate of adverse events was stratified by 
distal vs. proximal DVT and fatal vs. non-fatal 
PE, using a conditional post-event distribution 
[28]. According to our assumptions, fatal 
events occurred in 12.5% and 25.0% of PE ca-
ses, for THR and TKR, respectively. Major 
bleedings represented 7.5% of all total blee-
ding events, for both THR and TKR patients. 
Table IIIa and Table IIIb illustrate, respecti-
vely, adverse events and death incidence rates 
(by drug and indication) and conditional distri-
bution of post-event rates.
Economic data and assumptions 
on resource consumption
As the Italian SSN perspective was adopted in 
the analysis, only direct healthcare costs were 
measured. Overall VTE prevention therapy 
costs, inpatient costs for THR and TKR surge-
ry, costs of VTE complications and bleedings 
were identified in our research. Figure 2 shows 
daily costs for pharmacological treatment.
Treatment
THR TKR
Total VTE 
+ all cause 
death rate (%)
Bleeding 
events rate 
(%)
Total VTE 
+ all cause 
death rate (%)
Bleeding 
events rate 
(%)
a) Incidence of VTE and bleeding events
Apixaban 1.9 8.7 17.4 5.6
Low molecular weight heparins 5.4 9.4 27.4 7.2
Rivaroxaban 1.6 9.4 14.2 7.6
Dabigatran 4.8 10.0 26.3 7.0
Fondaparinux 1.7 8.7 11.3 6.2
THR TKR
b) Distributions of VTE events and bleeding by severity/type
PE events (% of total events) 3.6 3.6
Fatal (% of PE events) 12.5 25.0
Non-fatal (% of PE events) 87.5 75.0
Symptomatic DVT events (% of total events) 2.6 4.5
Distal (% of symptomatic DVT events) 16.7 80.0
Proximal (% of symptomatic DVT events) 83.3 20.0
Asymptomatic DVT events (% of total events) 93.8 91.4
Distal (% of asymptomatic DVT events) 73.8 91.2
Proximal (% of asymptomatic DVT events) 26.2 8.8
Non-VTE death events (% of total events) 3.5 3.5
All VTE events + non-VTE deaths (% of total events) 100.0 100.0
Major bleedings (% of total bleeding events) 7.5 7.5
Non major bleedings (% of total bleeding events) 34.1 34.1
Minor bleedings(% of total bleeding events) 58.3 58.3
All bleeding events (% of total events) 100.0 100.0
Table III. Efficacy data used in the model: a) adverse events and death incidence rates; b) conditional distribution of post-event rates
Figure 2. Daily treatment costs of therapies indicated in VTE prevention 
(enoxaparin 40 mg: 4,000 International Units – IU)
OD = once daily; TD = twice daily
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 - Additional costs of VTE inpatient com-
plications were varied of +10%, compa-
red to base-case analysis;
 - Percentage of patients receiving apixaban 
was varied of +10%, compared to apixa-
ban patient share in the base-case.
RESULTS
According to patient population and tre-
atment assumptions, the estimated number of 
patients (THR and TKR) is 134,533 at Year 1, 
141,672 at Year 2 and 149,190 at Year 3. In 
Scenario B, the estimated number of patients 
treated with apixaban would be 1,613 at Year 
1, 5,309 at Year 2 and 9,839 at Year 3. Main 
results of the budget impact analysis are illu-
strated in Table V.
In Scenario A (i.e. apixaban not reimbursed 
by the SSN) the increasing number of THR 
and TKR interventions over time translates 
into a budget impact increase for the SSN 
(+1.81%: Year 2 vs. Year 1; +1.71%: Year 3 
vs. Year 2); index hospitalizations represents 
the budget impact driver for the SSN, ac-
counting for 98.83% of overall costs, consi-
dering the 3-year time horizon of the analysis. 
The budget impact associated to Scenario B 
(introduction of apixaban in the Italian mar-
ket) and Scenario A (non-reimbursement sce-
nario) would be similar: €3,641,168,854 and 
€3,641,223,204, respectively. Therefore Sce-
nario B would determine cumulative cost sa-
vings for €54,350 vs. Scenario A in the first 
three years, with a cost-saving profile achie-
ved in each of the three years analyzed. Also, 
Time 
horizon
Scenarios
Overall direct healthcare costs (€)
Apixaban
2.5 mg TD
Enoxaparin
40 mg OD
Rivaroxaban
10 mg OD
Dabigatran
220 mg OD
Fondaparinux
2.5 mg OD
Total
Year 1 Scenario A 0 1,061,917,884 46,115,222 36,201,725 48,230,524 1,192,465,356
Scenario B 14,297,284 1,049,183,674 45,562,267 35,767,641 47,652,169 1,192,463,036
Difference (B-A) 14,297,284 -12,734,210 -552,955 -434,084 -578,355 -2,320
Year 2 Scenario A 0 1,021,322,981 81,844,878 60,453,713 50,381,598 1,214,003,171
Scenario B 45,471,602 983,050,448 78,778,249 58,188,587 48,493,671 1,213,982,557
Difference (B-A) 45,471,602 -38,272,533 -3,066,629 -2,265,126 -1,887,927 -20,614
Year 3 Scenario A 0 1,004,262,729 104,867,596 72,810,347 52,814,005 1,234,754,677
Scenario B 81,400,279 938,030,298 97,952,558 68,009,203 49,330,923 1,234,723,261
Difference (B-A) 81,400,279 -66,232,431 -6,915,038 -4,801,144 -3,483,082 -31,416
All Years Scenario A 0 3,087,503,594 232,827,696 169,465,785 151,426,127 3,641,223,204
Scenario B 141,169,165 2,970,264,420 222,293,074 161,965,431 145,476,763 3,641,168,854
Difference (B-A) 141,169,165 -117,239,174 -10,534,622 -7,500,354 -5,949,364 -54,350
Table V. Results of the budget impact analysis: scenarios comparison
Costs for complications (VTE events and 
bleedings) requiring hospitalization are 
shown in Table III. In our model, only sym-
ptomatic VTE events determined healthcare 
costs for SSN. It was assumed that 100% of 
bleedings and 68.9% of symptomatic VTE 
events occurred at the time of hospital stay 
during the surgical replacement procedure 
[32]. In these cases an additional cost (40% 
of the DRG 78 tariff for PE events [33]; attri-
butable DVT cost from PATHOS study [27]) 
was summed up to the standard hospital cost 
for THR or TKR (without complications) to 
take into account the higher burden for hospi-
tals. A similar approach was used to estimate 
additional costs due to bleeding, by grade of 
severity. The remaining VTE events (31.1% 
of all cases) were assumed to occur after ho-
spital discharge and to require hospital ad-
mission, according to costs and tariffs repor-
ted in Table IV.
SENSITIVITY ANALYSIS
A range of one-way deterministic sensitivity 
analyses was carried out to test robustness of 
base-case results. Specifically, variation of 
the following parameters was tested:
 - Drug administration costs during THR/
TKR hospitalization were included;
 - Drug acquisition costs of nOACs were 
reduced of -40%, compared to base-case 
analysis;
 - Discount rates for costs after year 1 were 
varied from 0% to 7% (discount in the 
base-case: 3.5%);
THR TKR Sources and assumptions
a) Hospital costs for replacement surgery and complications
Hospital costs (without complications) 8,765 8,759 PATHOS study [27], average cost per intervention (without 
complications)
Symptomatic VTE PE 1,510 1,510 40% of DRG 78 tariff (pulmonary embolism); TUC 2009 [34]
Distal VTE 1,023 529 PATHOS study [27], additional costs due to distal VTE
Proximal VTE 1,023 529 PATHOS study [27], additional costs due to proximal VTE
Bleedings Major 1,267 1,267 40% of DRG 174 (gastro-intestinal hemorrhage with 
complications); TUC 2009 [34]
Non major 754 754 40% of DRG 175 (gastro-intestinal hemorrhage with 
complications); TUC 2009 [34]
Minor 41 41 National formulary of ambulatory specialist interventions, 
year 2009 [34]
b) Cost of complications (after hospital discharge)
Symptomatic VTE PE 3,773 3,773 DRG 78 tariff (pulmonary embolism); TUC 2009 [34]
Distal/proximal DVT, 
requiring hospitalization
2,310 2,310 DRG 128 tariff (deep vein thrombo-phlebitis); TUC 2009 [34]
Distal/proximal DVT, NOT 
requiring hospitalization
232 232 Nuijten MJC et al [35]
Table IV. Hospital costs for a) replacement surgery and in-hospital VTE complications; b) after hospital discharge
*DRG: diagnosis related group. **TUC: unified conventional tariff.
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the amount of cost savings sharply increases 
over time, as a consequence of the progressi-
ve replacement of LMWHs with nOACs.
Index hospitalizations represents the cost dri-
ver in the SSN perspective, being 98.83% of 
total direct healthcare costs. Excluding index 
hospitalization costs (for THR or TKR), drug 
costs account for 52.1% and 52.4% of total 
costs in Scenario B (apixaban reimbursed) 
and in Scenario A (apixaban not reimbursed), 
respectively (Figure 3). As a matter of fact, 
these costs (€22.24 million for Scenario A 
and €22.37 million for Scenario B) are relati-
vely negligible, compared to inpatient costs 
for surgery replacement (€3.60 billion), 
which are the most relevant budget impact 
contributor of the analysis.
In Figure 4, the evolution of drug costs and 
VTE (inpatient and outpatient) costs in the 
Figure 3. Composition of direct healthcare costs
Figure 4. Drug therapy and complications costs: scenario B vs. scenario A
 - Additional costs of VTE inpatient com-
plications were varied of +10%, compa-
red to base-case analysis;
 - Percentage of patients receiving apixaban 
was varied of +10%, compared to apixa-
ban patient share in the base-case.
RESULTS
According to patient population and tre-
atment assumptions, the estimated number of 
patients (THR and TKR) is 134,533 at Year 1, 
141,672 at Year 2 and 149,190 at Year 3. In 
Scenario B, the estimated number of patients 
treated with apixaban would be 1,613 at Year 
1, 5,309 at Year 2 and 9,839 at Year 3. Main 
results of the budget impact analysis are illu-
strated in Table V.
In Scenario A (i.e. apixaban not reimbursed 
by the SSN) the increasing number of THR 
and TKR interventions over time translates 
into a budget impact increase for the SSN 
(+1.81%: Year 2 vs. Year 1; +1.71%: Year 3 
vs. Year 2); index hospitalizations represents 
the budget impact driver for the SSN, ac-
counting for 98.83% of overall costs, consi-
dering the 3-year time horizon of the analysis. 
The budget impact associated to Scenario B 
(introduction of apixaban in the Italian mar-
ket) and Scenario A (non-reimbursement sce-
nario) would be similar: €3,641,168,854 and 
€3,641,223,204, respectively. Therefore Sce-
nario B would determine cumulative cost sa-
vings for €54,350 vs. Scenario A in the first 
three years, with a cost-saving profile achie-
ved in each of the three years analyzed. Also, 
Time 
horizon
Scenarios
Overall direct healthcare costs (€)
Apixaban
2.5 mg TD
Enoxaparin
40 mg OD
Rivaroxaban
10 mg OD
Dabigatran
220 mg OD
Fondaparinux
2.5 mg OD
Total
Year 1 Scenario A 0 1,061,917,884 46,115,222 36,201,725 48,230,524 1,192,465,356
Scenario B 14,297,284 1,049,183,674 45,562,267 35,767,641 47,652,169 1,192,463,036
Difference (B-A) 14,297,284 -12,734,210 -552,955 -434,084 -578,355 -2,320
Year 2 Scenario A 0 1,021,322,981 81,844,878 60,453,713 50,381,598 1,214,003,171
Scenario B 45,471,602 983,050,448 78,778,249 58,188,587 48,493,671 1,213,982,557
Difference (B-A) 45,471,602 -38,272,533 -3,066,629 -2,265,126 -1,887,927 -20,614
Year 3 Scenario A 0 1,004,262,729 104,867,596 72,810,347 52,814,005 1,234,754,677
Scenario B 81,400,279 938,030,298 97,952,558 68,009,203 49,330,923 1,234,723,261
Difference (B-A) 81,400,279 -66,232,431 -6,915,038 -4,801,144 -3,483,082 -31,416
All Years Scenario A 0 3,087,503,594 232,827,696 169,465,785 151,426,127 3,641,223,204
Scenario B 141,169,165 2,970,264,420 222,293,074 161,965,431 145,476,763 3,641,168,854
Difference (B-A) 141,169,165 -117,239,174 -10,534,622 -7,500,354 -5,949,364 -54,350
Table V. Results of the budget impact analysis: scenarios comparison
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due to the good risk-benefit profile, the mode 
of administration, and the daily costs, which 
are comparable with LMWHs and fondapari-
nux. This analysis highlights two important 
aspects regarding VTE prevention. First, the 
introduction of the new oral anti-coagulant 
apixaban would not determine a budget im-
pact increase for the SSN. More precisely, 
the analysis shows that a net economic be-
nefit, even if small, will be achieved in the 
next years with apixaban reimbursement and 
usage. Second, the economic impact of phar-
macological prevention of VTE is relatively 
low, compared to the annual amount of ho-
spital costs for THR and TKR interventions. 
VTE prevention is prescribed for about 15-30 
days, according to type of prevention, type 
of drug and patients’ characteristics, and this 
sporadic usage makes the treatment afforda-
ble for the SSN. Our model estimates that 
only 1.7% of healthcare resources is alloca-
ted in VTE prevention, and that the introduc-
tion of new agents will not modify (increase) 
the number of treated patients, as almost all 
patients already receive a pharmacological 
VTE prevention.
In our analysis, we adopted a conservative 
approach for our base-case analysis. Drug ad-
ministration costs (for parenteral treatments) 
were not included in the base-case analysis, 
assuming that these costs would be covered 
within the DRG (i.e. no extra-costs for hospi-
tals). Also, we intentionally decided to focus 
on direct healthcare costs only, although the 
inclusion of indirect costs and the adoption 
of a societal perspective would have been 
favourable for apixaban and nOACs in gene-
ral. Finally, and most importantly, apixaban 
daily cost only includes rebates granted to 
the official ex-manufacturer price, as the fi-
nal result of government negotiations. Unlike 
the other treatments included in the analysis, 
first three years after apixaban reimburse-
ment is illustrated. Drug investment with 
apixaban is fully set off by cost savings for 
avoided VTE episodes.
Based on clinical assumptions, Scenario B 
would be also associated to a reduction of 
VTE and bleeding events. In particular, over 
the entire period (3 years) apixaban introduc-
tion would be associated to the reduction of: 
symptomatic VTE and pulmonary embolism 
incidence (-106 non-fatal cases and -7 fatal 
cases vs. Scenario A); asymptomatic VTE in-
cidence (-1,645 non-fatal cases vs. Scenario 
A); bleedings incidence (-186 cases vs. Sce-
nario).
Results of sensitivity analysis, shown in Ta-
ble VI, confirm that findings of the base-case 
study are robust.
In all scenarios tested, the inclusion of apixa-
ban in the Italian market remains favourable. 
Inclusion of administration costs during in-
dex hospitalization, -40% reduction of drug 
costs, and +100% increase of apixaban usage 
would be the most beneficial scenarios, al-
though the net benefit remains quite limited, 
if cost savings are compared with the overall 
budget impact of THR and TKR manage-
ment, which is almost exclusively driven by 
hospital costs (+10% of hospital costs deter-
mines a +9.88% of overall budget impact for 
the SSN). The other scenarios included in the 
sensitivity analysis are affected by negligible 
fluctuations.
DISCUSSION
In a few years, nOACs have become an im-
portant alternative to previous and well esta-
blished pharmacological treatments indicated 
in VTE prevention after orthopaedic surge-
ry. Currently LMWHs remain the standard 
of care/prevention in this indication, but the 
usage of nOACs has been rapidly increasing, 
N. Description of the analysis
Direct healthcare costs differences (€) – Scenario B-A Overall direct 
healthcare costs 
with Scenario B
All Years (€)
Year 1 Year 2 Year 3 All years
1 Base-case -2,320 -20,614 -31,417 -54,351 3,641,168,854
2 Inclusion of drug administration costs -18,840 -70,431 -117,942 -207,213 3,645,038,210
3 40% reduction of nOACs daily costs -38,618 -127,999 -215,692 -382,309 3,639,346,360
4 Costs not discounted -2,320 -21,336 -33,654 -57,310 3,771,601,407
5 Costs discounted at 7% rate -2,320 -19,940 -29,395 -51,655 3,522,003,963
6 10% increase of VTE complications 
during THR/TKR hospitalization
-3,497 -24,301 -37,950 -65,747 3,642,770,443
7 10% decrease of VTE complications 
during THR/TKR hospitalization
-1,143 -16,929 -24,886 -42,958 3,639,567,445
8 100% increase of apixaban patient share -5,147 -41,184 -62,981 -109,312 3,641,113,891
Table VI. Results of sensitivity analysis
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reasons: i) these drugs would be prescribed to 
a much larger number of patients, compared 
to the current situation; ii) pharmacological 
treatment SPAF is chronic; iii) likely, nOACs 
will be also distributed by public pharmacies, 
with additional costs for the SSN. All these 
reasons would lead to a substantial increase 
of economic resources to fund this class of 
agents, which will likely have to be offset by 
a price reduction of nOACs daily cost. Since 
the level of price discount for apixaban, riva-
roxaban and dabigatran is hard to predict, we 
decided to apply a -40% reduction, which is 
the average final price rebate for enoxaparin 
(from ex-manufacturer price to the distribu-
tion price). This analysis shows that further 
discounts applied to nOACs would allow an 
additional slightly reduction of the budget 
impact, although majority of costs always 
depend on index hospitalizations.
The expected price reduction of nOACs in 
the next few years represents a definitive con-
firmation of affordability of nOACs usage in 
VTE prevention. On the other side, the pos-
sible approval and market authorization of 
these promising therapies in SPAF raise re-
levant questions on their cost-effectiveness, 
requiring further economic studies aimed to 
evaluate sustainability and comparative cost-
effectiveness vs. available treatment options.
further rebates granted to hospitals have not 
been estimated/included, due to the very re-
cent decision of reimbursement. Reasonably, 
an additional reduction of apixaban costs 
would reflect into additional cost savings for 
the SSN.
The selection of alternative scenarios to 
test with sensitivity analysis was performed 
adopting different points of view. For as-
sumptions affected by uncertainty (positive/
negative), we evaluated standard sensitivity 
analysis. This was the case of discount rates 
and additional inpatient costs due to VTE 
complications. With regard of apixaban usa-
ge, the effect of a limit-case analysis, assu-
ming to double apixaban patients’ share, 
was analyzed. Although this case may seem 
unlikely, it was tested to assess whether lar-
ge, unexpected variations of the market could 
determine substantial budget impact increase, 
which would not be affordable, considering 
this period of economic constraints. Finally, 
the -40% reduction was chosen to take into 
account the future price erosion for nOACs 
at the time of launch of the second indication: 
prevention of stroke in patients with atrial fi-
brillation (SPAF). If the Italian Drug Agency 
(AIFA) will grant approval of nOACs in this 
new indication, a price reduction is likely to 
expect, and will be triggered by the following 
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